Featured News

Daratumumab combination treatment approved for NHS use in England and Wales through the Cancer Drugs Fund

Myeloma patients at first relapse in England and Wales will now be able to access the new treatment of daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone on the NHS after it was approved for use through the Cancer Drugs Fund (CDF).

Read full story

Published
12 March 2019